Ryoji Noritake is the Chair of Health and Global Policy Institute (HGPI), a Tokyo-based independent health policy think tank established in 2004. He joined HGPI in 2005 and led patient advocacy international collaboration and disaster recovery projects. He previously served as Asia-Pacific Lead for Project HOPE, a US-based medical humanitarian aid organization, where he worked on public-private partnerships for disaster relief and health promotion projects across the Asia-Pacific region. He was a member of WHO's Expert Consultation on Impact Assessment Working Group (2012), a Visiting Scholar at the National Graduate Institute for Policy Studies (2016-2020), and serves on the World Dementia Council. He holds a degree from Keio University's Faculty of Policy Management and an MSc in Medical Anthropology from the University of Amsterdam. He became Executive Director in 2016 and Chair in 2024.

Elias Mossialos is the Cheng Yu Tung Chair in Global Health and Director of LSE Health at the London School of Economics and Political Science. His research spans health systems and policy, focusing on healthcare financing, regulation, access, quality, pharmaceutical policy, cancer care, digital health, and antimicrobial resistance. He pioneered the Options Market for Antibiotics, enabling early-stage investment by offering payers rights to purchase antibiotics at reduced prices upon market approval. He also developed securitisation mechanisms for funding performance-based annuities for cell and gene therapies for rare diseases. Professor Mossialos has received numerous awards including the Andrija Stampar Medal (2010) for contributions to European public health, the ACRL Choice Award (2021), two Baxter Awards (2002, 2007), and the Helen-Clark-JoPPP Award (2022). Under his leadership, LSE Health received the UK's Queen's Anniversary Prize in 2009. His public roles include Member of Parliament in Greece (2009-2012), Minister of State (2011), Chair of the Parliament's Social Security Committee, and Scientific Director of the WHO's Pan-European Commission on Health and Sustainable Development (2020-2021), addressing post-COVID health policy priorities.

A Healthcare Communicator, he graduated from the Faculty of Medicine, The University of Tokyo in 2000 and joined NHK, covering healthcare and medical issues around the world. In 2016, after serving as a Visiting Scholar at Stanford University, he founded the Medical Journalism Study Group and became its Representative Director. He has been a Visiting Associate Professor at Hiroshima University’s Faculty of Medicine since 2020, and an Associate Professor at Musashi University’s Faculty of Sociology since 2025. His notable works include the NHK Special "The Danger of Sleep Debt." He received the Special Award of the Yahoo! News Japan Personal Author Award in 2019.

He served as Vice Chairman of UBS Group AG (2010–2019), Chairman of Syngenta and the Syngenta Foundation (2013–2017), and Chairman of Swiss Holdings (2013–2015). He was CFO at ABB (2005–2013), interim CEO in 2008, and European CFO of Baxter. He spent 18 years at Dow Chemical, leading international finance as Global Polyolefins & Elastomers CFO. He began his career at the Belgium branch of Continental Illinois Bank and holds a degree in Applied Economics and an MBA from KU Leuven.

Keizo Takemi is Chairperson of the Liberal Democratic Party (LDP) Members' General Assembly in the House of Councillors and former Minister of Health, Labour and Welfare (2023-2024). Born in Tokyo in 1951, he graduated from Keio University in 1974 and completed his master's in 1976. He was a professor at Tokai University before being elected to the House of Councillors in 1995, now serving his fifth term. He previously served as State Secretary for Foreign Affairs, Senior Vice Minister for Health, and Chair of the Foreign Affairs and Defense Committee. Prof. Takemi has held numerous international positions including WHO Goodwill Ambassador for UHC (2019-2022), Co-Chair of UNDP's Advisory Panel on Human Security, and member of various UN and WHO committees. He was also a research fellow at Harvard School of Public Health (2007-2009) and a TV news anchor (1984-1987).

Completed the Master’s Program at the Division of Health Sciences and Nursing, Graduate School of Medicine, University of Tokyo in 2003. Doctor (by dissertation only) of Health Sciences in the same field.
Served as an assistant at the Faculty of Human Sciences, Waseda University and assistant professor at the University of Tokyo, Healthcare Quality Assessment. Appointed as associate professor at the University of Tokyo, Healthcare Quality Assessment in April 2009 and professor at the same in April 2014 (part-time from May 2015). Has served as professor at Health Policy and Management, Keio University School of Medicine since May 2015.

Graduated from Keio University School of Medicine. After working as a physician at national hospitals, joined the Ministry of Health, Labour and Welfare (MHLW). For about 25 years, he was in charge of medical administration and local government administration (Mie and Chiba Prefecture). After serving as Director of the Cancer and Disease Control Division, and Director of the Geriatric Health Division of MHLW, I have been in my current position since August 2024.

Dr. Suzuki graduated from Keio University School of Medicine in 1984 and joined the Ministry of Health. He earned MPH and MSc degrees from Harvard University (1989-90) and a PhD from Keio University (1996). In 1998, he was seconded to WHO as Assistant Director-General (executive director level) for four years. His career at the Ministry of Health, Labour and Welfare included positions as Director of Health Research and Development (2005), Director of Health Services for the Elderly (2006), Medical Insurance Director (2010), and Surgeon General of the Defense Ministry (2012). He served as Deputy Minister for Technical Affairs (2014), Commissioner of the Health Insurance Bureau (2016), and Vice-Minister for Health/Chief Medical & Global Health Officer (2017-2020). He became Vice President of International University of Health and Welfare in 2021 and President in 2022.

Dr. Shuhei Nomura is a Professor at Keio University Global Research Institute (KGRI) and an expert in epidemiology and biostatistics. His research spans global health policy, disease burden, nutrition, and disaster risk management. He collaborates with international organizations such as the World Health Organization (WHO) and the Bill & Melinda Gates Foundation. Among his various roles, he serves on the Global Burden of Disease (GBD) Scientific Council and is a Senior Fellow at the Center for Asia-Pacific Resilience and Innovation (CAPRI). He contributes to evidence-based policymaking and bridges research and practice to strengthen health systems worldwide.

Dr. Reiko Hayashi is the Director-General of Japan's National Institute of Population and Social Security Research (IPSS). She holds bachelor's and master's degrees in Health Sciences and a bachelor's in Architecture from the University of Tokyo, a master's from the University of Paris, and a PhD in Policy Studies from the National Graduate Institute for Policy Studies. She served as technical advisor to Senegal's Minister of Health, lecturer at the University of Tokyo GCOE program, and Director of International Research and Deputy Director-General at IPSS before assuming her current position in 2024. Her research focuses on health and longevity, migration, population development, and population policies. She serves as board member of the Asian Population Association (former president), the Population Association of Japan, Japan Association for Global Health, and on various government committees for the Ministry of Health, Labour and Welfare.

A bereaved family member who lost their spouse to scirrhous gastric cancer. Graduate of Ochanomizu University. Worked as a teacher at Gakushuin until 2014. Having experienced the importance of information firsthand as a patient's family member, they worked together with the Japan Gastric Cancer Association to organize the National Gastric Cancer Caravan nationwide and to create gastric cancer treatment guidelines for patients. She is working for raising awareness of cancer and making policy proposals in the hope of creating a society that is easy for everyone to live in.

Graduated from the University of Tsukuba School of Medicine in 1998 and joined Mitsui Memorial Hospital (Internal Medicine). In 2000, specialized in Gastroenterology, and in 2003, entered the doctoral program at the University of Tokyo Graduate School of Medicine. Began working in home healthcare in 2006 and became Chairman of Yushoukai Medical Corporation in 2008. Selected as a Global Ageing Influencer at the 2018 Ageing Asia Innovation Forum. Since 2021, serving as an expert member of the Cabinet Office’s Regulatory Reform Council (Healthcare/Welfare). Also a board member of Japanese Associations for Home Medical Care and Japanese Society of Home-Based Emergency Medicine.

1975-1981 School of Medicine, Keio University (M.D.) 1981-1985 Graduate School of Medicine, Keio University (PhD.) 1986-1994 Researcher, Section Head: Research Institute, National Cancer Center 1994-2003 Division Chief: Research Institute, East, National Cancer Center 2003-2013 Division Chief: Research Center for Cancer Prevention and Screening, National Cancer Center 2013-2021 Director: Center for Public Health Sciences, National Cancer Center 2021-2023 Director: National Institute of Health and Nutrition, NIBIOHN 2023- Current Position.
Specialty: Epidemiology and prevention research of NCDs

After graduating from Keio University School of Medicine in 1994, Prof. Koichi Fukunaga completed his residency at Keio University Hospital, worked as a research fellow at the University of Tokyo Graduate School, served as a senior resident at Keio University Hospital, and as a staff physician at National Hospital Organization Minami-Yokohama Medical Center. He was a research fellow at Harvard Medical School's Brigham and Women's Hospital and Chief of Internal Medicine at Saitama Social Insurance Hospital before returning to Keio University as Assistant Professor, Associate Professor, and eventually Professor (2019) in the Department of Internal Medicine (Respiratory Medicine). He became Vice Director of Keio University Hospital in 2021 and Chair of the Department of Internal Medicine in 2023. In 2020, he served as Chief Scientific Officer of Japan's COVID-19 Task Force.

Prof. Chang-Chuan Chan is a distinguished professor at National Taiwan University, former Dean of the College of Public Health, and director of major health centers. He represents Taiwan in APRU and M8 Alliance, and advises Taipei City. An expert in air pollution and environmental health, he earned his ScD from Harvard and has published over 200 papers globally.

Mr. Scheijgrond is VP of Government and Public Affairs at Royal Philips, leading global relations on geopolitical, trade, and healthcare system challenges. He co-founded the WEF Health Partnership, serves as a UNFPA Commissioner, and drives international collaborations. He has prior experience at UNEP and in corporate sustainability roles. He holds an MSc in Environmental Technology from Wageningen University, Netherlands.

Fumihiko Ugajin leads IQVIA Japan, driving data-driven healthcare solutions and digital transformation within the life sciences industry. With nearly two decades of experience in strategy, technology, and analytics, he has played a pivotal role in shaping the future of healthcare innovation in Japan.
Since joining IQVIA (formerly IMS) in 2006, Fumi has held key leadership positions across strategy consulting, sales, operations, and general management. As former Senior Vice President and General Manager of Technology and Analytics Solutions, he spearheaded initiatives that leveraged advanced data analytics and AI to enhance healthcare outcomes. Under his leadership, IQVIA Japan is developing its expertise in real-world evidence, digital health, and commercial strategy as it continues to drive impactful change in Japan's evolving healthcare landscape.
Prior to IQVIA, Fumi held positions at Accenture and Hikari Tsushin, bringing a wealth of experience in business transformation and strategic consulting. He holds a BA in Economics from the University of Tokyo and an MHA in Public Health from the University of North Carolina at Chapel Hill.
A strong advocate for digital health innovation, Fumi is committed to enabling IQVIA Japan to unlock the potential of AI, big data, and precision medicine to improve patient care and shape the future of healthcare.

A graduate of the University of Tokyo's Faculty of Law, Hiroyuki Komatsu began his career at Nissho Iwai Corporation (now Sojitz). He later transitioned to ITX Corporation, where he was engaged in M&A and investment projects. Demonstrating his entrepreneurial leadership, he took on the role of President and CEO of Olympus Business Creation Shanghai, successfully launching a new venture in China.
Mr. Komatsu joined Roche Diagnostics in 2013. As Head of Molecular Diagnostics, he achieved remarkable business growth during the COVID-19 pandemic by establishing a new ecosystem with key stakeholders, including government bodies and major commercial labs. After serving as Head of Marketing, he was appointed to his current role as Head of Business Innovation in 2023. In this capacity, he now leads new business development, strategic partnerships, innovation, and digital business initiatives for the company. He also served as a director for the Japan Association of Clinical Reagents Industries from 2017 to 2020.

Joined the Ministry of Health, Labour and Welfare (MHLW) in 1991; served as Planning Officer, General Affairs Division, Minister's Secretariat in 2008; Director, Corporate Pension National Pension Fund Division, Pension Bureau in 2014; Director, Disability Welfare Division, Disability Welfare Department, Social Affairs and Support Bureau in 2016; Director, Planning Division, same Department in 2018; Director, General Affairs Division, Pension Bureau in 2020; and then Deputy Director-General, Cabinet Secretariat with Assistant Deputy Director General in 2021 Deputy Director-General of the Digital Agency's Service Group for the People from 2021, and from July 2023 Assistant Vice-Minister for Pharmaceutical Industry Promotion and Medical Information Management, Ministry of Health, Labour and Welfare.

He was a health specialist at the World Bank group and a research fellow at Beth Israel Deaconess Medical Center/Harvard Medical School. Dr. Tsugawa’s research has been published in leading medical and health policy journals including JAMA, JAMA Internal Medicine, BMJ, and Lancet. Dr. Tsugawa’s research has also been featured in several media outlets including The New York Times, The Washington Post, and National Public Radio. Dr. Tsugawa received PhD in Health Policy from Harvard University, MPH from Harvard School of Public Health, and MD from Tohoku University School of Medicine in Japan. His research is supported by the National Institute of Health. He is an author of multiple books including “Causal Inference in Economics” (with Professor Makiko Nakamuro, published by DIAMOND, Inc.) and “Introduction to Health Policy” (Igaku-Shoin, Ltd.). He is an expert in health policy and health economics.

After graduating from Keio University and working at institutions including the Bank of Japan, Professor Nakamuro assumed her current position. She obtained an MPA and Ph.D. from Columbia University. She specializes in economics of education. She serves as an expert committee member for the government's Digital Administrative and Financial Reform Council, Regulatory Reform Promotion Council, and others. Her publications include 'Science-Based (Evidence-Based) Child-Rearing' (which sold 78,000 copies within 3 months of release), 'The Economics of "Academic Achievement"' (published by Discover Twenty-One), which was the runner up for the 2016 Business Book Award and has sold over 370,000 copies, and 'The Economics of "Cause and Effect"' (co-authored, published by Diamond), which was ranked #1 in Weekly Diamond's 2017 Best Economics Books. Since September 2021, she has been serving as a Senior Expert (Digital Education Coordinator) at the Digital Agency.

Born in 1959, Hitoshi Fukuhara was diagnosed with acute aortic dissection at the age of 54 in 2013, requiring emergency surgery to replace the ascending aorta with an artificial graft. Subsequently, he experienced a stroke, aortic valve regurgitation, and coronary artery stenosis. To date, he has undergone a total of five major surgeries, including three open-heart surgeries and two stent graft procedures. In 2019, he established the Heart Valve Voice, a general incorporated association, and assumed the role of Representative Director. Since 2021, he has also served as an Advisor to the Japanese Circulation Association. With the mission of “improving the present and future of people living with heart valve disease,” he engages in public awareness initiatives, patient support, and policy advocacy, while also participating in satoyama (woodland) conservation and maintenance activities in the Tokyo metropolitan area.

Takafumi Horii leads approximately 3,700 employees across Commercial, R&D and Operations with annual revenue of about 500 billion yen since July 2022. Prior to joining AstraZeneca, he served as Senior Vice President and Head of Japan Oncology Business Unit at Takeda Pharmaceutical Company. His international experience includes roles as VP & Area Head of the Near-east, Middle-east and Africa covering 21 countries, President in Taiwan, and leadership positions in emerging markets and China. Horii began his career at Canon Inc., later joined a US-based IT startup in Japan where he led a consulting team. He has expanded his leadership through assignments in Dubai, Taiwan, Shanghai and Singapore. He currently serves as Vice Chair of the European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) and Standing Director of the Japan Pharmaceutical Manufacturers Association (JPMA). He holds an MBA from the Darden School of Business, University of Virginia.

＜Current Position＞
・Member of House of Representatives（7th times）
・Minister for Digital Transformation
・Minister in Charge of Digital Administrative and Fiscal Reform
・Minister in charge of Administrative Reform
・Minister in charge of the National Civil Service System
・Minister in charge of Cybersecurity
・Minister of State for Regulatory Reform
・Chairperson, Policy Research Council, Federation of Tokyo Prefecture LDP Party Branches

＜Career History＞
・Graduated from Waseda University Faculty of Law
・3rd generation middle wholesaler at Ota Fruit and Vegetable Market
・President, Tokyo Junior Chamber
・Lecturer at Keio University Graduate School
・Parliamentary Vice-Minister of Economy, Trade and Industry
・State Minister of Cabinet Office (in charge of disaster prevention, administrative reform, IT policy, space policy, Promotion of Science and Technology and Innovation, Cool Japan Strategy, local development, National Strategic Special Zones, etc.)
・Director, Masayoshi Ohira Foundation
・Head, Project Team on the Evolution and Implementation of AI, LDP
・Head, Project Team on the web3, LDP
・Head, Fusion Energy Project Team, LDP
・Secretary General, New Capitalism Implementation Headquarters, LDP

The Rt Hon. the Lord Lansley CBE, a Conservative member of the House of Lords since 2015, served as MP for South Cambridgeshire (1997–2015), holding major government roles, including Secretary of State for Health, Leader of the Commons, and Lord Privy Seal. He is active in key committees, currently serving on the UK Engagement with Space Committee.

Emil Levendoğlu has served as Minister and Deputy Head of Mission at the British Embassy in Tokyo since October 2023. With a background in academia, finance, HM Treasury, and the Cabinet Office, he has led on financial policy, international relations, and security. He advocates for workplace mental health and is a keen cyclist and Arsenal FC supporter, with degrees from Oxford, Cambridge, and UC Berkeley.